 |
Hana Biosciences Announces Second Quarter 2006 Results
Aug 14, 2006
|
17.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 14, 2006--Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical
company focused on advancing cancer care, announced today financial
results for the second quarter of 2006.Non-GAAP net loss of $6.5 million for the three months ended
June 30, 2006 compared to $2.1...
|
|
Hana Biosciences Announces Conference Call on Second Quarter 2006 Financial Results and Business Update
Aug 3, 2006
|
7.2 KB |
|
| |
OUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 3, 2006--Hana Biosciences (NASDAQ:HNAB - News), a biopharmaceutical company focused on advancing cancer care, will announce its 2006 second quarter results on Monday, August 14th, prior to the open of the financial markets.
Following the announcement, Hana Biosciences' management will host a...
|
|
Hana Biosciences Initiates Phase I Clinical Trial of a Targeted Chemotherapy Agent for Patients With Advanced Solid Tumors
Aug 3, 2006
|
10.2 KB |
|
| |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 3, 2006--Hana Biosciences (NASDAQ:HNAB - News), a biopharmaceutical company focused on advancing cancer care, today announced the initiation of a Phase I clinical study of Sphingosome Encapsulated Vinorelbine in patients with advanced solid tumors.
This Phase I study is designed to asses...
|
|
Hana Biosciences to Present at the Canaccord Adams Summer Seminar
Aug 2, 2006
|
6.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 2, 2006--Hana Biosciences (NASDAQ:HNAB - News), a biopharmaceutical company focused on advancing cancer care, announced today that Mark Ahn, PhD, President & Chief Executive Officer, will present a company update at the Canaccord Adams Summer Seminar on Tuesday, August 8th at 3:30pm EDT in t...
|
|
Hana Biosciences to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Jul 10, 2006
|
6.7 KB |
|
| |
South San Francisco, CA (July 10, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, announced today that Dr. Greg Berk, Senior Vice President and Chief Medical Officer, will present a company update at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Wednesday, July...
|
|
Hana Biosciences Submits Zensana™ (Ondansethron HCL) Oral Spray New Drug Application (NDA) to the U.S. Food and Drug Administration
Jun 30, 2006
|
45.0 KB |
|
| |
South San Francisco, CA (June 30, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, today announced that the company has submitted a New Drug Application (NDA) for ZensanaTM (ondansetron HCl) Oral Spray to the U.S. Food and Drug Administration (FDA) seeking marketing approval for the pre...
|
|
Hana Biosciences to Present at Jefferies & Company Life Sciences Coneference
Jun 23, 2006
|
6.8 KB |
|
| |
South San Francisco, CA (June 23, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, announced today that Mark Ahn, PhD, President & Chief Executive Officer, will present a company update at the Jefferies & Company Life Sciences Conference on Wednesday, June 28th, at 11:15am EDT i...
|
|
Hana Biosciences Set to Join Both the Russell 3000 Index and the Russell Microcap Index
Jun 20, 2006
|
8.6 KB |
|
| |
South San Francisco, CA (June 20, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, will join the Russell 3000® Index and the Russell Microcap™ Index when the Russell Investment Group reconstitutes its family of U.S. Indexes on June 30, 2006, according to a preliminary list of...
|
|
Hana Biosciences Receives Orphan Drug Designation for Ropidoxuridine (IPdR), for the Treatment of Malignant Glioma
Jun 9, 2006
|
8.8 KB |
|
| |
San Francisco, CA (June 9, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, announced that the U.S. Food and Drug Administration has granted orphan drug designation for Ropidoxuridine (IPdR) for the treatment of malignant glioma, which makes up approximately half of all primary brain tu...
|
|
Hana Biosciences to Present at Pacific Growth Equities Life Sciences Growth Conference
Jun 8, 2006
|
6.8 KB |
|
| |
th San Francisco, CA (June 8, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, announced today that Mark Ahn, PhD, President & Chief Executive Officer, will present a company update at the Pacific Growth Equities Life Sciences Growth Conference on Tuesday, June 13th, at 3:00pm PDT i...
|
|
Hana Biosciences Presents Zensanatm (Ondansetron HCl) Oral Spray Pivotal Trials at ASCO
May 31, 2006
|
11.5 KB |
|
| |
South San Francisco, CA (May 31, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, will present pivotal trials on their most advanced drug candidate, ZensanaTM (ondansetron HCl) Oral Spray. As previously reported, pivotal trials were completed in early 2006 and the company believes endp...
|
|
Hana Biosciences to Present Talotrexin (PT-523) Phase I Clinical Trials in Solid Tumors and Non Small Cell Lung Cancer (NSCLC) at ASCO
May 30, 2006
|
9.1 KB |
|
| |
South San Francisco, CA (May 30, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, announced that Phase I trials in solid tumors and non small cell lung cancer (NSCLC) with Talotrexin (PT-523) will be presented at the upcoming 42nd Annual Meeting of the American Society of Clinical Oncol...
|
|
Hana Biosciences to Present at the Friedman, Billings, Ramsey Growth Conference
May 30, 2006
|
6.8 KB |
|
| |
South San Francisco, CA (May 30, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, announced today that Mark Ahn, PhD, President & Chief Executive Officer, will present a company update at the Friedman, Billings, Ramsey Growth Conference on Wednesday, May 31st, at 12:00pm EDT in Room...
|
|
Hana Biosciences to Present at the Canaccord Adams Life Sciences Conference
May 26, 2006
|
6.7 KB |
|
| |
South San Francisco, CA (May 26, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, announced today that Fred Vitale, Vice President and Chief Business Officer, will present a company update at the Canaccord Adams Life Sciences Mini-Conference on Wednesday, May 31st, 2006 at 2:00pm EDT in...
|
|
Hana Biosciences to Present Data On Two Products and Debut Proprietary OPTISOME Platform At the American Society of Clinical Oncology Annual Meeting
May 25, 2006
|
10.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 25, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced that it will be presenting data and debuting its OPTISOME™ Technology Platform at the upcoming 43rd Annual American Society of Clinical ...
|
|
Hana Biosciences Receives Orphan Drug Designation for Talotrexin (PT-523), for the Treament of Acute Lyphoblastic Leukemia
May 22, 2006
|
9.7 KB |
|
| |
South San Francisco, CA (May 22, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, announced that the U.S. Food and Drug Administration has granted orphan drug designation for Talotrexin (PT-523) in patients with acute lymphoblastic leukemia (ALL). Talotrexin, a novel nonpolyglutamatabl...
|
|
Hana Biosciences to Raise $40.0 Million in Common Stock Financing
May 17, 2006
|
7.4 KB |
|
| |
South San Francisco, CA (May 17, 2006) – Hana Biosciences (NASDAQ: HNAB) announced today that it has obtained commitments from several institutional investors to purchase approximately 4.7 million shares of its common stock at a price of $8.50 per share, including the purchase of approximately 72,000 shares by affiliated investors at $9.07...
|
|
Hana Biosciences Reaafirms Expected Timing of First NDA Filing
May 9, 2006
|
7.6 KB |
|
| |
South San Francisco, CA (May 9, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, provided an update today on its most advanced drug candidate, Zensana™ (ondansetron HCl) Oral Spray. Hana completed pivotal trials for Zensana™ in early 2006, which it believes met endpoints suf...
|
|
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmacueticals
May 8, 2006
|
14.7 KB |
|
| |
South San Francisco, CA (May 8, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, completed its previously announced licensing transaction with Inex Pharmaceuticals Corporation (TSX: IEX). Under the terms of the transaction, Hana paid INEX a total of $11.5 million, consisting of cash an...
|
|
Hana Biosciences Reports First Quarter 2006 Results
May 4, 2006
|
47.0 KB |
|
| |
South San Francisco, CA (May 4, 2006) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care reported a net loss of $3.4 million, or $0.15 per share for the quarter ended March 31, 2006, compared to a net loss of $2.4 million, or $0.18 per share, in 2005. Total operating expenses for the first quart...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
Shareholder Briefcase
Printed Materials
Email Alerts
Download Library
RSS News Feeds